Status and phase
Conditions
Treatments
About
A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment before.
Full description
multiple sites, randomized, open-label, controlled study design. 64 eligible subjects will be enrolled in this study, and they will be randomly assigned to each group in a 1:1:1:1 proportion, 16 subjects in each group. Each site will compete to enroll subjects.
The 4 groups are as follows: Group A:Lipovirtide 10mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily); Group B:Lipovirtide 40mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily); Group C:Lipovirtide 60mg+3TC+TDF(LP-80:once every 2 weeks;3TC+TDF:once daily); Group D:DTG +3TC + TDF(once daily).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
64 participants in 4 patient groups
Loading...
Central trial contact
Ping Ma, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal